MA32271B1 - Composes inhibiteurs de kinases raf et procedes d'utilisation - Google Patents

Composes inhibiteurs de kinases raf et procedes d'utilisation

Info

Publication number
MA32271B1
MA32271B1 MA33202A MA33202A MA32271B1 MA 32271 B1 MA32271 B1 MA 32271B1 MA 33202 A MA33202 A MA 33202A MA 33202 A MA33202 A MA 33202A MA 32271 B1 MA32271 B1 MA 32271B1
Authority
MA
Morocco
Prior art keywords
methods
reg
inhibitory compounds
kinase inhibitory
compounds
Prior art date
Application number
MA33202A
Other languages
Arabic (ar)
English (en)
Inventor
Kateri A Ahrendt
Alexandre J Buckmelter
Jonas Grina
Joshua D Hansen
Ellen R Laird
David Moreno
Brad Newhouse
Li Ren
Steven Mark Wenglowsky
Bainian Feng
Janet Gunzner
Kim Malesky
Simon Mathieu
Joachim Rudolph
Zhaoyang Wen
Wendy B Young
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of MA32271B1 publication Critical patent/MA32271B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Des composés de formule i sont utiles pour inhiber des kinases raf. La présente invention concerne des procédés d'utilisation de composés de formule i, ainsi que des stéréo-isomères, des tautomères, des promédicaments, et des sels pharmaceutiquement acceptables de ceux-ci, en vue du diagnostic, de la prévention, ou du traitement, in vitro, in situ, et in vivo, de ces troubles dans les cellules de mammifères. La présente invention concerne également des conditions pathologiques associées.
MA33202A 2008-02-29 2010-09-24 Composes inhibiteurs de kinases raf et procedes d'utilisation MA32271B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3283908P 2008-02-29 2008-02-29
PCT/US2009/035380 WO2009111278A2 (fr) 2008-02-29 2009-02-27 Composés inhibiteurs de kinases raf et procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA32271B1 true MA32271B1 (fr) 2011-05-02

Family

ID=40935896

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33202A MA32271B1 (fr) 2008-02-29 2010-09-24 Composes inhibiteurs de kinases raf et procedes d'utilisation

Country Status (16)

Country Link
US (1) US8338452B2 (fr)
EP (1) EP2265608A2 (fr)
JP (1) JP2011513330A (fr)
KR (1) KR20100122505A (fr)
CN (1) CN102015707A (fr)
AR (1) AR070535A1 (fr)
AU (1) AU2009222143A1 (fr)
CA (1) CA2716951A1 (fr)
CL (1) CL2009000447A1 (fr)
EC (1) ECSP10010510A (fr)
IL (1) IL207843A0 (fr)
MA (1) MA32271B1 (fr)
MX (1) MX2010009410A (fr)
PE (1) PE20091561A1 (fr)
TW (1) TW200940540A (fr)
WO (1) WO2009111278A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
AR072657A1 (es) * 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
CA2716947A1 (fr) * 2008-02-29 2009-09-11 Array Biopharma Inc. Derives d'imidazo[4,5-b]pyridine utilises comme inhibiteurs de raf
FR2941948B1 (fr) * 2009-02-12 2013-04-05 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
CA2738573C (fr) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions et utilisations associees
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
PE20141360A1 (es) 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
JP6118808B2 (ja) 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
FR3000492B1 (fr) * 2012-12-28 2015-09-11 Oribase Pharma Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
FR3000494B1 (fr) * 2012-12-28 2015-08-21 Oribase Pharma Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases
FR3000493A1 (fr) * 2012-12-28 2014-07-04 Oribase Pharma Nouveaux inhibiteurs de proteines kinases
WO2014128235A1 (fr) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Méthodes de traitement du cancer et de prévention de résistance aux médicaments
HK1214533A1 (zh) 2013-03-15 2016-07-29 基因泰克公司 治疗癌症和预防癌症耐药性的方法
RU2015149937A (ru) * 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
CU24398B1 (es) * 2013-08-02 2019-04-04 Pfizer 3-(piperidin,pirrol o azetidin)-indoles sustituidos útiles como inhibidores rorc2
WO2015191986A1 (fr) 2014-06-13 2015-12-17 Genentech, Inc. Méthodes de traitement et de prévention de la résistance du cancer aux médicaments
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
WO2017087851A1 (fr) 2015-11-19 2017-05-26 Genentech, Inc. Méthodes de traitement du cancer au moyen d'inhibiteurs de b-raf et d'inhibiteurs de point de contrôle immunitaires
EP3579872A1 (fr) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk
CA3086765A1 (fr) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Systemes de culture de cellules souches pour cellules souches epitheliales colonnaires, et leurs utilisations
CA3129665A1 (fr) 2019-03-21 2020-09-24 Onxeo Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CA3158541A1 (fr) * 2019-12-10 2021-06-17 Cosimo Dolente Nouveaux inhibiteurs de braf en tant que "paradox breakers"
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
EP4788839A1 (fr) 2023-10-03 2026-08-12 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de mélanome
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
WO2026090116A2 (fr) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026090245A1 (fr) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Utilisation d'inhibiteurs ras pour traiter un cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (fr) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026112260A1 (fr) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026122764A2 (fr) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026128688A2 (fr) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026161839A1 (fr) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ186175A (en) 1977-01-27 1980-03-05 Shionogi & Co Meta-sulphonamidobenzamide derivatives
ATE291011T1 (de) 1997-12-22 2005-04-15 Bayer Pharmaceuticals Corp Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
JP4437270B2 (ja) 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
NZ505845A (en) 1997-12-22 2003-10-31 Bayer Ag Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (fr) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
EP2298311B1 (fr) * 1999-01-13 2012-05-09 Bayer HealthCare LLC Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030207914A1 (en) * 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
AU2003245700A1 (en) 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
MXPA04009541A (es) * 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
CN1744899A (zh) 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
US20050004133A1 (en) 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
AU2004246800B2 (en) * 2003-06-13 2008-12-04 Novartis Ag 2-aminopyrimidine derivatives as Raf kinase inhibitors
US7691870B2 (en) * 2003-07-11 2010-04-06 Merck Patent Gmbh Benzimidazole carboxamides as raf kinase inhibitors
WO2005004864A1 (fr) * 2003-07-11 2005-01-20 Merck Patent Gmbh Derives de benzimidazoles utilises comme inhibiteurs de kinase raf
DE10337942A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
KR100793095B1 (ko) * 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
WO2005034869A2 (fr) * 2003-10-08 2005-04-21 Irm Llc Composes et compositions convenant comme inhibiteurs de proteine-kinases
EP1682126B1 (fr) * 2003-10-16 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la raf kinase
WO2005037285A1 (fr) * 2003-10-16 2005-04-28 Chiron Corporation Quinoxalines, quinolines, isoquinolines et quinazolines 2,6-bisubstituees servant d'inhibiteurs a la kinase raf pour le traitement du cancer
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
US20090118261A1 (en) * 2004-08-31 2009-05-07 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
AU2005278961A1 (en) * 2004-09-01 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as B-Raf inhibitors
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2583096A1 (fr) * 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines en tant qu'inhibiteurs b-raf
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
TW200634003A (en) 2004-12-22 2006-10-01 Astrazeneca Ab Chemical compounds
EP1833829A2 (fr) 2004-12-23 2007-09-19 F. Hoffmann-Roche AG Imidazo- et pyrrolo-pyridines à substitution benzamide comme inhibiteurs de protéine kinase
CA2592118C (fr) * 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Derives d'uree en tant que modulateurs d'enzyme
WO2006079791A1 (fr) * 2005-01-25 2006-08-03 Astrazeneca Ab Composes chimiques
KR100919905B1 (ko) * 2005-01-26 2009-10-06 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
WO2006102079A1 (fr) * 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2, 4, 4b-triazafluoren-9-yle)-phenyl] benzamides utilises en tant qu'inhibiteurs de tyrosine/threonine kinase, en particulier la b-raf kinase
WO2006124731A2 (fr) 2005-05-12 2006-11-23 Irm Llc Composes et compositions utilise(e)s en tant qu'inhibiteurs de proteines-kinases
WO2006124780A2 (fr) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
WO2006124462A2 (fr) * 2005-05-13 2006-11-23 Irm, Llc Composes et compositions convenant comme inhibiteurs de proteine kinase
AU2006272951A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
US7566716B2 (en) * 2005-05-20 2009-07-28 Array Biopharma Inc. Imidazopyrazines as Raf inhibitor compounds
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2007017143A1 (fr) 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Derives de l'azabenzimidazole, leur fabrication et leur utilisation en tant qu'agents anticancereux
AU2006279992A1 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2006284751A1 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
EP1926737B1 (fr) * 2005-09-15 2017-03-15 F. Hoffmann-La Roche AG Dérivés d'acide 4-amino-thiéno[3,2-c]pyridine-7-carboxylique
WO2007056625A2 (fr) * 2005-11-04 2007-05-18 Smithkline Beecham Corporation Inhibiteurs de thienopyridine b-raf kinase
WO2007067444A1 (fr) * 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Composes bicycliques ayant une activite inhibitrice de kinase
CA2632929A1 (fr) * 2005-12-22 2007-06-28 Astrazeneca Ab Composes chimiques
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
WO2007076460A2 (fr) 2005-12-23 2007-07-05 Kalypsys, Inc. Nouveaux thiazole-urees substitues utiles en tant qu'inhibiteurs de proteine-kinases
WO2007076474A1 (fr) * 2005-12-23 2007-07-05 Kalypsys, Inc. Nouveaux amides pyridinyloxy et pyrimidinyloxy substitués utilisés comme inhibiteurs de protéines kinases
JP2009532449A (ja) * 2006-04-05 2009-09-10 アストラゼネカ アクチボラグ 抗癌活性のある置換キナゾリン
WO2007113558A2 (fr) * 2006-04-05 2007-10-11 Astrazeneca Ab Composés chimiques
JP2009534364A (ja) * 2006-04-18 2009-09-24 アストラゼネカ アクチボラグ キナゾリン−４−オン誘導体、それらの製造方法およびそれらを含有する医薬組成物
BRPI0716477A2 (pt) * 2006-09-06 2014-03-18 Hoffmann La Roche Derivados heteroarila como inibidores de quinase protéica
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AU2007305016B2 (en) * 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2008044688A1 (fr) 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Dérivé de l'urée
EP1914234A1 (fr) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
RU2009122670A (ru) * 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008112695A2 (fr) 2007-03-12 2008-09-18 Irm Llc Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci
WO2008124393A1 (fr) 2007-04-04 2008-10-16 Irm Llc Derives de benzothiazole et leur utilisation en tant qu'inhibiteurs des proteines kinases
WO2008144253A1 (fr) 2007-05-14 2008-11-27 Irm Llc Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
BRPI0813356A2 (pt) * 2007-06-15 2014-12-30 Irm Llc Inibidores de proteína quinase e métodos para uso dos mesmos
US20110053932A1 (en) * 2007-06-21 2011-03-03 Irm Llc Protein Kinase Inhibitors and Methods for Using Thereof
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
JP5270553B2 (ja) * 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
EP2184285B1 (fr) * 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son utilisation
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
AR072657A1 (es) * 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
CA2716947A1 (fr) * 2008-02-29 2009-09-11 Array Biopharma Inc. Derives d'imidazo[4,5-b]pyridine utilises comme inhibiteurs de raf
AU2009226136B2 (en) * 2008-03-17 2013-08-15 Ambit Biosciences Corporation Quinazoline derivatives as RAF kinase modulators and methods of use thereof
GB0807609D0 (en) * 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8158636B2 (en) * 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) * 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8110576B2 (en) * 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
CN104530052A (zh) * 2008-06-10 2015-04-22 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물

Also Published As

Publication number Publication date
US20110110889A1 (en) 2011-05-12
EP2265608A2 (fr) 2010-12-29
CA2716951A1 (fr) 2009-09-11
WO2009111278A2 (fr) 2009-09-11
TW200940540A (en) 2009-10-01
ECSP10010510A (es) 2010-10-30
AU2009222143A1 (en) 2009-09-11
MX2010009410A (es) 2010-11-30
CL2009000447A1 (es) 2010-01-04
WO2009111278A3 (fr) 2010-07-15
US8338452B2 (en) 2012-12-25
IL207843A0 (en) 2010-12-30
KR20100122505A (ko) 2010-11-22
CN102015707A (zh) 2011-04-13
JP2011513330A (ja) 2011-04-28
PE20091561A1 (es) 2009-10-30
AR070535A1 (es) 2010-04-14

Similar Documents

Publication Publication Date Title
MA34234B1 (fr) Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
WO2009111278A3 (fr) Composés inhibiteurs de kinases raf et procédés d'utilisation
SG178900A1 (en) Raf inhibitor compounds and methods of use thereof
SG178899A1 (en) Raf inhibitor compounds and methods of use thereof
MA33614B1 (fr) Composés de benzoxépine inhibiteurs de pi3k et leurs procédés d'utilisation
PH12013501779B1 (en) Pyrrolopyridines as kinase inhibitors
WO2010003022A8 (fr) Dérivés d'isoindolone utilisés en tant qu'inhibiteurs de kinase mek et procédés d'utilisation correspondants
MY158829A (en) 5-anilinoimidazopyridines and methods of use
MA31339B1 (fr) Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation
IL205490A0 (en) 8 - anilinoimidazopyridines and their use as anti - cancer and /or anti - inflammatory agents
MX2021004410A (es) Inhibidores de la proteina tirosina fosfatasa.
TW200801012A (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
WO2008028141A3 (fr) Composés inhibiteurs de la kinase raf et procédés d'utilisation de ceux-ci
UA116774C2 (uk) Інгібітори серин/треонінкінази
WO2006125101A3 (fr) Composes inhibiteurs raf et procedes d'utilisation de ceux-ci
WO2007027855A3 (fr) Composes inhibiteurs de la raf kinase et procedes d'utilisation de ceux-ci
PH12013502369A1 (en) Diazacarbazoles and methods of use
WO2008157179A3 (fr) Azaindoles n-substitués et procédés d'utilisation
MA31146B1 (fr) Composes inhibant la phosphoinositide 3 kinase et procedes d'utilisation
MX2011009167A (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MX338504B (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
TN2012000192A1 (fr) N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf